Erectile Dysfunction: Evaluation and Stepwise Treatment
Cardiovascular risk stratification, structured PDE5 inhibitor selection, second-line therapy escalation, and indications for surgical intervention — framed around the AUA guideline and the recognition that new-onset ED is often the earliest sign of systemic vascular disease.
Executive Summary
S1. Pathophysiology and Etiologic Categories
Penile erection is a neurovascular event coordinated by parasympathetic outflow from S2–S4 spinal cord segments and the cavernous nerves traveling alongside the prostatic capsule. Sexual stimulation triggers nitric oxide (NO) release from non-adrenergic non-cholinergic (NANC) nerves and endothelium; NO activates guanylate cyclase in cavernosal smooth muscle, generating cGMP, which causes smooth muscle relaxation, sinusoidal expansion, and arterial inflow. Expanding sinusoids compress subtunical venous outflow against the rigid tunica albuginea, producing the veno-occlusive mechanism. Phosphodiesterase type 5 (PDE5) degrades cGMP — its inhibition prolongs and amplifies erection in the presence of sexual stimulation but does not initiate erection without it.
Disruption at any step produces ED. The dominant categories overlap heavily and most patients have multifactorial disease:
| Category | Mechanism | Common Causes |
|---|---|---|
| Vasculogenic | Arterial insufficiency or veno-occlusive failure | Atherosclerosis, hypertension, diabetes, hyperlipidemia, smoking, metabolic syndrome |
| Neurogenic | Disrupted parasympathetic signaling or NO release | Diabetes (autonomic neuropathy), spinal cord injury, MS, Parkinson, post-pelvic surgery (radical prostatectomy, cystectomy), pelvic radiation |
| Endocrine | Hormonal driver insufficient | Hypogonadism (low testosterone), hyperprolactinemia, thyroid dysfunction, Cushing |
| Drug-induced | Pharmacologic interference | Beta-blockers, thiazides, spironolactone, SSRIs, finasteride/dutasteride, GnRH agonists, opioids, cimetidine |
| Psychogenic | Anxiety, performance anxiety, depression, relationship factors | Often coexists with organic ED; situational pattern (preserved nocturnal/morning erections) |
| Anatomic / Structural | Direct mechanical impairment | Peyronie disease, prior trauma, congenital curvature, post-priapism fibrosis |
The vascular hypothesis of ED has reframed primary care evaluation. Penile arteries are 1–2 mm in caliber compared to coronary (3–4 mm) and internal carotid (5–7 mm) arteries — equivalent atherosclerotic plaque burden produces clinically significant obstruction in penile circulation years earlier. Several cohort studies demonstrate that men with new-onset ED have a 1.5–2× elevated risk of myocardial infarction, stroke, and cardiovascular mortality over the subsequent 5–10 years independent of traditional risk factors. ED is therefore a "window into the cardiovascular system" — the encounter is an opportunity for primary cardiovascular prevention.
S2. Evaluation and Cardiovascular Risk Assessment
History — Structured ED Inquiry
- Onset and tempo — sudden onset suggests psychogenic or vasculogenic event; gradual onset suggests progressive vascular or neurologic disease
- Pattern — preserved nocturnal/morning erections favor psychogenic; absent nocturnal erections point organic
- Situational vs global — context-specific failure (with one partner, not another) suggests psychogenic component
- Quality dimensions — penetration achievable? maintained until orgasm? satisfaction?
- Libido — low libido suggests hypogonadism; intact libido with mechanical failure favors vascular/neurogenic
- Ejaculation and orgasm — distinguish ED from premature ejaculation, retrograde ejaculation, anorgasmia
- Partner factors — partner's response, relationship satisfaction, sexual history of partner
- Validated questionnaire — IIEF-5 (5-item International Index of Erectile Function): score 22–25 = no ED; 17–21 mild; 12–16 mild-moderate; 8–11 moderate; 5–7 severe
Risk Factors and Comorbidities
- Cardiovascular disease, hypertension, hyperlipidemia, diabetes mellitus, metabolic syndrome
- Smoking — current or past pack-year history
- Alcohol and recreational drug use
- Obstructive sleep apnea
- Depression, anxiety, post-traumatic stress disorder
- Pelvic surgery (radical prostatectomy, cystectomy, low anterior resection), pelvic radiation
- Neurologic disease (MS, Parkinson, spinal cord injury)
- Endocrine disorders (hypogonadism, thyroid, prolactinoma, Cushing)
- Chronic kidney disease, end-stage renal disease
Medication Review — Common ED-Inducing Drugs
| Class | Examples | Mechanism / Notes |
|---|---|---|
| Antihypertensives | Thiazides, beta-blockers (propranolol > metoprolol > nebivolol/carvedilol), spironolactone, methyldopa, clonidine | Vascular and central effects; ARBs and ACEi are most ED-neutral choices |
| Antidepressants | SSRIs (paroxetine, sertraline), SNRIs, TCAs, MAOIs | Bupropion, mirtazapine, vilazodone are more ED-neutral |
| Antiandrogens | Finasteride, dutasteride (5α-reductase inhibitors), flutamide, bicalutamide, GnRH agonists, ketoconazole | Lower androgen activity; libido and erectile function affected |
| Opioids | Methadone, morphine, oxycodone, fentanyl (chronic) | Opioid-induced hypogonadism — measure testosterone |
| H2 blockers | Cimetidine | Antiandrogenic; ranitidine and famotidine less affected |
| Antipsychotics | First-generation, risperidone | Hyperprolactinemia → secondary hypogonadism |
| Recreational | Alcohol (chronic), cannabis (chronic), cocaine, amphetamines, anabolic steroids | Multiple mechanisms including HPG axis suppression |
Physical Examination
- General — body habitus, secondary sexual characteristics, gynecomastia, central obesity
- Cardiovascular — BP, pulses, bruits, signs of peripheral arterial disease
- Genital — penile size and curvature (Peyronie plaques on dorsum), testicular size and consistency (Prader orchidometer), inguinal exam
- Neurologic — lower extremity sensory exam, perianal sensation, anal sphincter tone, bulbocavernosus reflex, cremasteric reflex
- Digital rectal exam — prostate size and nodularity (BPH and screen for prostate cancer if age-appropriate)
Laboratory and Workup
| Test | Indication |
|---|---|
| Fasting lipid panel | All — cardiovascular risk |
| Fasting glucose / HbA1c | All — diabetes screening |
| Morning total testosterone (8–11 AM, ×2 if low) | Low libido, hypogonadism features, fatigue |
| Free testosterone, SHBG | Borderline total testosterone, obesity, cirrhosis |
| LH, FSH | Confirmed low testosterone — distinguish primary vs secondary hypogonadism |
| Prolactin | Low testosterone; low libido; visual symptoms (consider prolactinoma) |
| TSH | Symptoms of thyroid dysfunction |
| PSA (age-appropriate) | Per shared decision-making before testosterone replacement |
| Renal and hepatic function | Baseline before pharmacotherapy; chronic disease screening |
| Cardiovascular evaluation (stress test, CAC scoring) | Intermediate-risk men before resuming sexual activity; new-onset ED especially if sedentary or unable to climb 2 flights of stairs |
S3. First-Line Therapy — PDE5 Inhibitors
PDE5 inhibitors selectively block phosphodiesterase type 5 in cavernosal smooth muscle, prolonging cGMP-mediated vasodilation in response to sexual stimulation. They are equally efficacious across most causes (60–80% response), with selection driven by pharmacokinetics, lifestyle preferences, side-effect profile, and cost.
| Agent | On-Demand Dose | Onset | Duration | PDE5 Selectivity Notes |
|---|---|---|---|---|
| Sildenafil (Viagra) | 25–100 mg PO 30–60 min before activity | 30–60 min (delayed by fatty meal) | 4–6 hours | PDE6 cross-reactivity → blue-tinged vision (~3%) |
| Tadalafil (Cialis) on-demand | 10–20 mg PO 30 min before activity | 30 min (food-independent) | Up to 36 hours ("weekend pill") | PDE11 cross-reactivity → myalgia, back pain (~5%) |
| Tadalafil daily | 2.5–5 mg PO daily | Steady state | Continuous | Dual indication: ED + BPH/LUTS; greater spontaneity |
| Vardenafil (Levitra) | 5–20 mg PO 30–60 min before activity | 30–60 min (delayed by fatty meal) | 4–6 hours | QTc prolongation (avoid in long QT) |
| Avanafil (Stendra) | 50–200 mg PO 15–30 min before activity | 15–30 min (food-independent at 100 mg) | 4–6 hours | Highest PDE5 selectivity → fewer visual side effects |
Counseling Points for First Prescription
- Sexual stimulation is required — the medication does not produce erection without arousal
- Optimal timing varies — sildenafil/vardenafil empty stomach; tadalafil and avanafil food-independent
- Try at least 4–6 doses at maximum tolerated dose before declaring failure
- Common side effects: headache (15%), flushing (10%), dyspepsia (5%), nasal congestion (5%), back pain/myalgia (tadalafil)
- Stop and seek emergency care for: erection >4 hours (priapism), sudden vision loss (NAION), sudden hearing loss, chest pain
- Generic sildenafil and tadalafil are widely available at substantially reduced cost
Drug Interactions and Contraindications
| Interaction | Effect | Management |
|---|---|---|
| Nitrates (any form) | Life-threatening hypotension | ABSOLUTE contraindication; minimum 24h washout for sildenafil/vardenafil/avanafil; 48h for tadalafil before nitrate use |
| Riociguat (sGC stimulator) | Synergistic hypotension | ABSOLUTE contraindication |
| Alpha-blockers (tamsulosin, doxazosin, etc.) | Additive hypotension | Separate by 4 hours; start PDE5i at lowest dose; tadalafil 2.5–5 mg daily co-prescription preferred for BPH+ED |
| Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) | ↑ PDE5i levels | Reduce starting dose: sildenafil 25 mg, tadalafil 5 mg, vardenafil 2.5 mg, avanafil 50 mg |
| Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | ↓ PDE5i efficacy | May require dose increase or alternative therapy |
| Severe cardiovascular disease | Cardiac risk during sexual activity | Defer until stabilized; high-risk patients per Princeton III defer activity |
| Retinitis pigmentosa | Theoretical retinal effects | Avoid PDE5 inhibitors |
| Prior NAION | Risk of recurrence in fellow eye | Discuss risks; case-by-case decision |
S4. Second-Line and Adjunctive Therapies
Intracavernosal Injection (ICI)
Direct injection into the corpus cavernosum bypasses neurogenic and PDE5-dependent pathways, producing erection in 5–15 minutes regardless of psychological state. Effective in 70–80% of PDE5i non-responders.
- Alprostadil (Caverject, Edex) — Alprostadil 5–40 mcg ICI titrated; start at 2.5–5 mcg in office; titrate every 1–2 weeks based on response and pain
- Trimix (compounded) — Alprostadil 10 mcg/mL + Papaverine 30 mg/mL + Phentolamine 1 mg/mL; 0.1–1 mL injected; lower alprostadil dose reduces injection pain
- Bimix (alprostadil + papaverine) or quadmix (adds atropine) for refractory cases
Counseling and complications: teach injection technique (lateral aspect of penile shaft, alternate sides, rotate sites), maximum 3× weekly, no more than 1× daily. Risks: pain (20–30% with alprostadil, less with trimix), priapism (1–4% — seek care if >4 hours), corporal fibrosis, penile curvature with chronic use. Hold and reassess if priapism occurs.
Intraurethral Alprostadil (MUSE)
Alprostadil 125–1000 mcg intraurethral pellet via plastic applicator after voiding. Onset 5–10 minutes, duration 30–60 minutes. Less effective than ICI (~40% success). Adverse effects: urethral burning (~30%), hypotension, syncope (have patient sit/stand carefully). Avoid in pregnant partner without barrier protection.
Vacuum Erection Device (VED)
Mechanical device creates negative pressure to draw blood into cavernosa; constriction ring at base maintains erection (max 30 minutes). Non-pharmacologic option useful for: PDE5i non-responders/contraindications, post-prostatectomy penile rehabilitation, patients preferring drug-free option. 70–80% achieve usable erection. Disadvantages: erection feels "hinged" at base, cool temperature, ejaculation may be impaired, requires manual dexterity. Constriction ring >30 minutes risks ischemia.
Testosterone Replacement Therapy (When Hypogonadism Confirmed)
Confirmed hypogonadism (consistently low total testosterone <300 ng/dL on ≥2 morning samples) plus symptoms: testosterone replacement may improve libido and modestly enhance ED therapy response, but is not first-line for ED in eugonadal men.
- Testosterone gel 1.62%: 20.25–81 mg topically daily (AndroGel, Testim, Vogelxo)
- Testosterone cypionate 100–200 mg IM q1–2 weeks or Testosterone enanthate 100–200 mg IM q1–2 weeks
- Testosterone undecanoate 750 mg IM at 0, 4 wk, then q10 wk (Aveed)
- Monitor: testosterone level (mid-cycle for IM, anytime for daily gel), hematocrit (hold if >54%), PSA, lipid panel, prostate exam
Adjunctive — Low-Intensity Shock Wave Therapy (Investigational)
Low-intensity extracorporeal shock wave therapy (Li-ESWT) shows benefit in vasculogenic ED in some trials, possibly via neovascularization and stem cell recruitment. AUA 2024 guideline considers it investigational — not yet standard of care; should be performed within research or specialized clinical settings with informed consent about evidence quality.
S5. Surgical Therapy and Special Populations
Penile Prosthesis (Inflatable Penile Prosthesis — IPP)
Three-piece IPP (paired cavernosal cylinders + scrotal pump + retropubic reservoir) is the definitive surgical solution for refractory ED. AMS 700 (Boston Scientific) and Coloplast Titan are the dominant devices. Indications: failure or intolerance of medical therapy, severe Peyronie disease with deformity, post-priapism corporal fibrosis, post–radical prostatectomy refractory ED.
- Outcomes — >90% patient satisfaction, >85% partner satisfaction, >90% mechanical durability at 5 years, ~70% at 10 years
- Risks — infection (1–3%; lower with antibiotic-coated devices), mechanical failure (~5% at 5 years), erosion, persistent pain, length loss
- Preoperative optimization — HbA1c <8.5% (lower infection risk), urinary tract infection screening and treatment, smoking cessation, skin and oral hygiene
- Two-piece (no reservoir) and malleable prostheses — alternatives in patients with prior pelvic surgery, contraindications to reservoir placement, or desire for simpler device
Vascular Surgery (Highly Selected Candidates)
Penile arterial revascularization (microsurgical bypass) is reserved for young men (<50 years) with isolated post-traumatic arterial occlusion confirmed by penile duplex and arteriography. Not indicated for diffuse atherosclerotic ED. Performed at specialized centers.
Post–Radical Prostatectomy Penile Rehabilitation
Cavernous nerve injury during radical prostatectomy causes denervation, smooth muscle apoptosis, and corporal fibrosis. "Penile rehabilitation" aims to maintain cavernosal tissue health during the 6–24 month neurologic recovery window with one or more of:
- Tadalafil 5 mg PO daily or Sildenafil 50–100 mg PO 3×/week starting within weeks postoperatively
- Vacuum erection device daily without constriction ring (oxygenation goal)
- Intracavernosal injection if PDE5i fails — start early
- Counsel patient: erectile recovery is gradual; nerve-sparing technique, age, baseline function, and adjuvant therapy all influence outcome
Diabetes Mellitus
ED prevalence ~50% in men with DM, occurring 10–15 years earlier than non-diabetic peers. Multifactorial: vascular, neurogenic (autonomic neuropathy), endothelial dysfunction, frequent hypogonadism. Glycemic control modestly improves ED. PDE5 inhibitors remain first-line but response rates are lower (~50%); ICI works well when PDE5i fails.
Spinal Cord Injury
Erectile pattern depends on lesion level: upper motor neuron lesions (above T10) often retain reflexogenic erection (touch-induced) but lose psychogenic; lower motor neuron lesions (sacral) lose reflexogenic erection. PDE5 inhibitors effective in upper motor lesions. ICI effective regardless of lesion level. Vibratory stimulation can elicit reflexogenic erection in select patients.
Peyronie Disease
Acquired penile curvature from tunical fibrous plaque — pain in acute phase, deformity in stable phase. Coexists with ED in ~30%. Workup: photographic documentation of erect penis (pre-treatment baseline), penile duplex if surgical planning. Treatment: Collagenase clostridium histolyticum 0.58 mg intralesional × up to 8 injections for stable curvature 30–90°; surgical plication or grafting for refractory or severe cases. PDE5i treats coexistent ED.
Practice Insights: ED Is a CV Sentinel, PDE5 Inhibitor Counseling Drives Success, Avoid the Nitrate Combination
ED Is a Cardiovascular Sentinel — Workup Accordingly
The single most important diagnostic framing experienced practice emphasizes is that ED is a vascular disease that often precedes overt cardiovascular disease by 2-5 years. The penile arteries are smaller than coronary arteries; endothelial dysfunction manifests as ED before progressing to angina or MI. Workup at every new ED diagnosis: detailed cardiovascular risk assessment, fasting lipid panel, fasting glucose/HbA1c, blood pressure, BMI; calculate 10-year ASCVD risk; consider formal stress testing if symptoms suggest underlying CAD or high risk. Additional workup: total testosterone (morning, fasting; if low repeat to confirm); TSH; PSA in age-appropriate men; review medications for ED-inducing agents (beta-blockers, thiazides, SSRIs, finasteride, anti-androgens). The "ED visit" becomes a cardiovascular health visit that may save the patient's life.
PDE5 Inhibitor Counseling Is the Outcome Driver
In practice for PDE5 inhibitor success, experienced clinicians find that counseling about correct use matters more than which agent. Sildenafil 50-100 mg: take 30-60 minutes before sex on empty stomach (high-fat meal reduces absorption), duration 4-6 hours, plan around the timing. Tadalafil 10-20 mg PRN: take 30 minutes before sex, duration up to 36 hours, food does not affect absorption, allows greater spontaneity. Tadalafil 2.5-5 mg daily: continuous low-dose daily for men prioritizing spontaneity over PRN timing. Vardenafil 10-20 mg: similar to sildenafil with similar timing. Avanafil 100-200 mg: shortest onset (15-30 min). Counsel about: needing sexual stimulation (PDE5 inhibitors don't cause spontaneous erections), adequate trial of 4-8 attempts at maximum tolerated dose before declaring failure, side effects (headache, flushing, dyspepsia, visual changes, nasal congestion — usually mild and transient).
Nitrate + PDE5 Combination Is Absolute Contraindication
The single most consequential safety issue is the absolute contraindication of nitrate-PDE5 inhibitor combination. The combination causes severe, potentially fatal hypotension. Contraindicated nitrates: nitroglycerin (SL, patch, IV), isosorbide dinitrate, isosorbide mononitrate, amyl nitrite, recreational "poppers". Time spacing: PDE5 inhibitor cannot be given within 24 hours of any nitrate dose (48 hours for tadalafil due to longer half-life); reverse — nitrates contraindicated within 24-48 hours of any PDE5 inhibitor exposure. For men with CAD requiring intermittent nitrate use: alternative ED therapies (vacuum device, intracavernosal injection, prosthesis) without absolute contraindication. Document in chart and instruct patient: never take a nitrate while on PDE5 inhibitor; inform any emergency provider of recent PDE5 inhibitor use. Alpha-blockers + PDE5: additive hypotension; lowest doses of each, separate timing (PDE5 at least 4 hours after alpha-blocker), monitor BP.
Second-Line Therapy Ladder for PDE5 Failures
For documented PDE5 inhibitor failures (adequate trial 4-8 attempts at maximum dose, taken correctly), the second-line ladder offers good options. Vacuum erection devices: non-invasive, no drug, reusable; effective for cooperative patients willing to integrate device use; usable for cardiac patients with PDE5 contraindication. Intraurethral alprostadil (MUSE): pellet inserted into urethra 5-10 minutes before sex; lower efficacy than injection but less invasive. Intracavernosal injection: alprostadil monotherapy, bimix (papaverine + phentolamine), or trimix (papaverine + phentolamine + alprostadil) — high efficacy (~85% response in PDE5 failures), but injection-related anxiety and rare priapism (treat with phenylephrine intracavernosal if >4 hours). Penile prosthesis (semi-rigid or inflatable 3-piece) — definitive surgical option with high satisfaction rates among well-selected patients who have failed less invasive options. Shockwave therapy: emerging evidence; not yet first-line standard.
Illustrative Scenario
A patient in his early sixties presented with 6-month history of progressive ED, previously prescribed sildenafil 50 mg PRN by outside provider — "didn't work" after 2 attempts. Reviewing history: he had taken the medication 10 minutes before sex after a steak dinner. Cardiovascular review: hypertension on metoprolol + HCTZ, dyslipidemia on atorvastatin, smoker 1 PPD × 30 years, sedentary, fasting glucose 118 (prediabetes). ED triggered comprehensive CV workup: 10-year ASCVD risk 22% (high), HbA1c 6.4%, lipid panel suboptimal, EKG showed left ventricular hypertrophy. Stress test showed reversible ischemia → cath revealed 75% LAD stenosis, treated with PCI. Concurrent ED management: counseling about correct PDE5 use (1 hour before, empty stomach), trial extended to sildenafil 100 mg with appropriate use → 6 of 8 attempts successful. Lifestyle interventions: smoking cessation program, structured exercise, Mediterranean diet. At 12-month follow-up: continued PDE5 success, post-PCI cardiac stable, smoking cessation achieved, 8 kg weight loss. ED was the symptom that prompted detection of significant CAD and life-saving intervention.
Practice Pattern Refinements vs Standard Algorithm
- ED visit = CV workup visit. ASCVD risk calculation, lipid panel, glucose/HbA1c, BP, BMI, medication review. Formal stress testing if symptoms or high risk. ED often precedes CAD by 2-5 years.
- PDE5 inhibitor counseling is the success driver. Sildenafil: 30-60 min before sex, empty stomach. Tadalafil: 30 min before or daily low-dose, food OK. Need sexual stimulation. 4-8 attempt trial at max dose before declaring failure.
- Nitrate + PDE5 absolute contraindication — document and counsel. 24-hour spacing minimum (48 hours for tadalafil). Patient must inform any ED provider of recent PDE5 use. Alpha-blockers additive hypotension — space and minimize doses.
- Second-line ladder for PDE5 failures. Vacuum device → MUSE → intracavernosal injection → penile prosthesis. ~85% response with intracavernosal in PDE5 failures. Penile prosthesis high satisfaction for failed less invasive options.
S6. Counseling, Lifestyle, and Long-Term Follow-Up
Lifestyle Interventions with Evidence
- Smoking cessation — improves vascular function within months; ED improvement at 1 year
- Weight loss — Mediterranean diet + exercise improves ED in obese men; 5–10% body weight loss measurable improvement
- Aerobic exercise — 40 minutes 4×/week of moderate intensity demonstrates IIEF improvement
- Reduced alcohol intake — chronic heavy use causes hypogonadism and ED; moderation recommended
- Diabetes glycemic control — glycemic improvement modestly benefits ED, though established disease may not fully reverse
- Blood pressure and lipid control — primary cardiovascular benefit; some antihypertensives and statins may improve endothelial function
- Sleep apnea treatment — CPAP therapy can improve ED in OSA patients
Partner and Relationship Counseling
- Include partner in evaluation when feasible — relationship satisfaction strongly mediates outcomes
- Address performance anxiety with reassurance and structured behavioral techniques
- Refer to sex therapist or couples counseling when psychogenic factors dominate or when relationship distress is significant
- Discuss expectations realistically — therapy enables function, but it does not guarantee perfect erections in every encounter
Follow-Up Schedule
- Initial follow-up 4–8 weeks after starting therapy — assess response, side effects, compliance, partner satisfaction
- Dose titration visits as needed
- Annual review — cardiovascular risk reassessment, medication review, hormonal assessment if indicated
- For testosterone replacement — hematocrit at 3, 6, 12 months then annually; PSA at baseline and annually; testosterone level 4–12 weeks after initiation
Counseling and lifestyle interventions deserve more emphasis than they typically receive. Smoking cessation is the single most impactful modifiable factor — smoking acutely impairs penile blood flow and chronically promotes endothelial dysfunction; cessation produces improvement in erectile function over 6-12 months. Weight loss in overweight/obese men: 5-10% weight loss measurably improves erectile function, particularly when combined with exercise (3-4 sessions/week of aerobic + resistance training). Mediterranean diet: epidemiologic data supports improvement in erectile function comparable to PDE5 inhibitor benefit in some studies — reasonable to recommend without overstating. Alcohol moderation: chronic heavy use impairs both libido and erectile function; reduction to ≤2 drinks/day often produces measurable improvement.
Sleep apnea screening and treatment in patients with risk factors (obesity, snoring, witnessed apneas, daytime sleepiness): CPAP therapy can substantially improve erectile function in OSA patients via testosterone normalization and endothelial repair. Glycemic control in diabetic patients with HbA1c targets <7% — though established diabetic ED is partially refractory to glycemic optimization (similar to neuropathy). Long-term follow-up: annual cardiovascular risk reassessment given ED as CV sentinel, periodic medication review for ED-inducing agents (beta-blockers, thiazides, SSRIs, finasteride), couples counseling referral if relationship distress, mental health referral if depression/anxiety significant. Patient education that ED is a medical condition, not a personal failure, reduces shame and improves treatment engagement.
Frequently Asked Questions
- Phimosis and Paraphimosis: Topical Steroids, Manual Reduction, and Circumcision Indications
- Microscopic Hematuria: AUA Risk Stratification, Cystoscopy & Imaging Strategy
- Vesicoureteral Reflux: Grading, VCUG/DMSA Imaging, CAP, and Endoscopic vs Surgical Repair
- Urge Urinary Incontinence: Evaluation and Treatment
- Benign Prostatic Hyperplasia: IPSS, Medical Therapy, and Surgical Options
- Bladder Cancer: NMIBC vs MIBC Diagnosis, BCG, Cystectomy, and Immunotherapy